Labetuzumab I-131

Drug Profile

Labetuzumab I-131

Alternative Names: Anti-CEA monoclonal antibody MN 14-I-131; CEA-Cide-I-131; hAFP-Y-90; Humanised anti-CEA monoclonal antibody MN 14-I-131; IMMU-111

Latest Information Update: 26 Aug 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Immunomedics
  • Class Antineoplastics; Monoclonal antibodies; Radiopharmaceuticals; Radiosensitisers
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Colorectal cancer
  • Discontinued Liver cancer; Thyroid cancer

Most Recent Events

  • 03 Jun 2008 Efficacy and adverse events data from a phase II trial in colorectal liver metastases presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO-2008)
  • 04 Jun 2007 Interim results from a phase II clinical trial in patients with resected liver metastases from primary colorectal cancer added to the adverse events and Cancer therapeutic trials sections
  • 19 Jun 2006 Data presented at the 42nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2006) have been added to the Cancer therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top